LFWD Stock Falls Despite Launch of Next-Generation Mobility ReWalk 7

Core Viewpoint - Lifeward Ltd. has launched the ReWalk 7 Personal Exoskeleton in the U.S., enhancing assistive technology for individuals with spinal cord injuries, showcasing the company's leadership and technological advancements in the industry [1][2][5]. Product Launch and Market Impact - The ReWalk 7 received FDA clearance in March 2025 and follows the ReWalk 6.0 system, which improved user capabilities for navigating stairs and curbs [2]. - The introduction of a Medicare reimbursement pathway in 2024 has facilitated broader market access for the ReWalk 7, supporting Lifeward's mission to empower the spinal cord injury community [2][5]. Technological Enhancements - The ReWalk 7 features cloud connectivity for data-driven updates, two customizable walking speeds, and a new crutch control unit for enhanced user control [7]. - Complementary devices, including a wrist control smartwatch and a mobile application, simplify mode selection and progress tracking, integrating the device into daily routines [7]. User-Centric Development - Lifeward collaborated with over two dozen end users and physical therapists to gather feedback, leading to improvements in training efficiency and safety [9]. - The development process included the introduction of a therapist handheld device for better session control, resulting in a device that enhances user confidence and control [9]. Financial Performance - Following the launch announcement, LFWD's shares increased by 1.4% on April 15, although the company has experienced an 18% decline in shares year-to-date, compared to an 11.1% decline in the industry and an 8.4% drop in the S&P 500 Index [4].